CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 67 enrolled
Drug / intervention
Intensity modulated radiation therapy (IMRT)radiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03953976
NCT03953976Phase 2Completed
CompareCT.gov

INRT- AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy Using Artificial Intelligence-Based Radiomics for Head and Neck Squamous Cell Carcinoma

University of Texas Southwestern Medical Center·interventional·Posted May 17, 2019·Updated Feb 19, 2026

In Brief

A Phase 2 clinical trial evaluating Intensity modulated radiation therapy (IMRT) for Head and Neck Squamous Cell Carcinoma. Completed, enrolled 67 participants across 1 site.

Detailed Summary

Elective nodal irradiation has been a longstanding standard-of-care in the management of mucosal squamous cell carcinoma of the head and neck. Recent studies have suggested that reduced elective dose and volume may be a viable approach to improve toxicity. In this study, we are eliminating the elective neck treatment, focusing therapy on involved and suspicious nodes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Squamous Cell Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 17, 2019
Enrollment StartJul 23, 2019
Primary CompletionNov 15, 2022
Study CompletionJan 22, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.1 years ago

Interventions

Intensity modulated radiation therapy (IMRT)radiation

Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy